Tag: Epcoritamab-bysp FDA approval

Home / Epcoritamab-bysp FDA approval

Categories

The FDA has granted expedited approval to epcoritamab-bysp for the treatment of R/R follicular lymphoma

June 2024: The Food and Drug Administration has given accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with recurr...
epcoritamab-bysp-fda-approval

Scan the code